×
About 1,763 results

ALLMedicine™ Lymphoblastic Lymphoma Center

Research & Reviews  507 results

Progression to B acute lymphoblastic leukemia in 8p11 myeloproliferative syndrome with ...
https://doi.org/10.1007/s12185-023-03577-z
International Journal of Hematology; Nakamura F, Seo S et. al.

Mar 18th, 2023 - 8p11 myeloproliferative syndrome is a rare hematological malignancy caused by the translocation of FGFR1. Patients present with a myeloproliferative neoplasm that frequently transforms into acute myeloid leukemia or T-lymphoblastic lymphoma/leukem...

Population pharmacokinetics of intramuscular recombinant Erwinia chrysanthemi asparagin...
https://doi.org/10.1111/cts.13499
Clinical and Translational Science; Lin T, Whigham T et. al.

Mar 18th, 2023 - JZP458 is a recombinant Erwinia chrysanthemi asparaginase for patients with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) who have developed hypersensitivity to Escherichia coli-derived asparaginases. A population pharmacokinetic...

Diagnosis and management of lymphoblastic lymphoma in children, adolescents and young a...
https://doi.org/10.1016/j.beha.2023.101449
Best Practice & Research. Clinical Haematology; Temple WC, Mueller S et. al.

Mar 13th, 2023 - Lymphoblastic lymphoma (LBL) is the second most common type of non-Hodgkin Lymphoma (NHL) in children, adolescents, and young adults (CAYA), accounting for 25-35% of all cases. T-lymphoblastic lymphoma (T-LBL) comprises 70-80% of cases, while prec...

Precursor B-cell Lymphoblastic Lymphoma in Children: Hacettepe Experience.
https://doi.org/10.1097/MPH.0000000000002656
Journal of Pediatric Hematology/oncology; Susam-Sen H, Yalcin B et. al.

Mar 11th, 2023 - The purpose of the study was to review the clinical and pathologic characteristics and treatment results of children with precursor B-cell lymphoblastic lymphoma. Of 530 children diagnosed with non-Hodgkin lymphomas between 2000 and 2021, 39 (7.4%...

Hopping as an Indicator of Chemotoxicity: Gait Analysis in Patients With Leukemia and L...
https://doi.org/10.1097/MPH.0000000000002645
Journal of Pediatric Hematology/oncology; Parker K, Durben N et. al.

Mar 11th, 2023 - Survivors of acute lymphoblastic leukemia (ALL) can experience chemotherapy-related changes in neuromuscular function, which can persist and impact the quality of life. Clinically, neuromuscular changes are assessed by observing gait. The primary ...

see more →

Drugs  8 results see all →

Clinicaltrials.gov  116 results

Venetoclax Basket Trial for High Risk Hematologic Malignancies
https://clinicaltrials.gov/ct2/show/NCT05292664

Mar 10th, 2023 - This is an investigator-initiated open-label multi-institutional phase I study of venetoclax combination therapy in both myeloid and lymphoid hematologic malignancies. This study is designed as a basket trial with three separate cohorts. All cohor...

XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia
https://clinicaltrials.gov/ct2/show/NCT05038644

Mar 9th, 2023 - The primary objective of this portion of the study is to determine a recommended phase II dose (RP2D) for XmAb18968. The trial will use a variation of the 3 + 3 design where both escalation and de-escalation are possible. There will be separate co...

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
https://clinicaltrials.gov/ct2/show/NCT03959085

Mar 9th, 2023 - PRIMARY OBJECTIVE: I. To determine in a randomized manner if the addition of 2 blocks of inotuzumab ozogamicin to modified Berlin-Frankfurt-Munster (mBFM) chemotherapy will improve 5-year disease-free survival (DFS) in children and young adults wi...

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
https://clinicaltrials.gov/ct2/show/NCT03914625

Mar 8th, 2023 - PRIMARY OBJECTIVES: I. To determine in a randomized manner if the addition of 2 cycles of blinatumomab to standard therapy improves disease-free survival (DFS) in patients with standard risk (SR) B-ALL and higher risk features (SR-High), and patie...

A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Lymphoma (B-ALL)
https://clinicaltrials.gov/ct2/show/NCT05460533

Mar 2nd, 2023 - Prior to initial tisagenlecleucel cell infusion, lymphodepleting chemotherapy (LDC) is required with standard dosing cyclophosphamide and fludarabine as per standard-of-care (fludarabine 30mg/m^2 /dose x 4 doses and cyclophosphamide 500mg/m^2 /dos...

see more →

News  74 results

Jimmy Carter's Melanoma; Post-Op Osimertinib Boosts OS; $83K for Unproven Therapy
https://www.medpagetoday.com/hematologyoncology/skincancer/103467

Mar 9th, 2023 - How the successful use of pembrolizumab (Keytruda) for former President Jimmy Carter's metastatic melanoma put "immunotherapy on the map." (Washington Post) A study of molecular changes observed in the breast tissue of transgender men undergoing a...

High-Dose MTX Does Not Reduce CNS Relapse in Pediatric ALL
https://www.medscape.com/viewarticle/985385

Dec 11th, 2022 - NEW ORLEANS — A study with the worthwhile goal of attempting to further improve outcomes and reduce toxicity of treatment for children and young adults with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma found that, contrary to long-...

Year in Review: Acute Lymphoblastic Leukemia
https://www.medpagetoday.com/hematologyoncology/leukemia/102051

Dec 5th, 2022 - The past year in acute lymphoblastic leukemia (ALL) research was marked by studies examining different ways of using chimeric antigen receptor (CAR) T-cell therapy, as well as efforts to de-intensify treatment. Tisagenlecleucel Effective in Younge...

ASH 2022: New Clinical Data Challenge Long-held Assumptions
https://www.medscape.com/viewarticle/984997

Dec 5th, 2022 - NEW ORLEANS — In addition to news on the latest in clinical care and drug development, some eyebrow-raising findings that challenge long-held but untested assumptions are promised from the annual meeting of the American Society of Hematology. The ...

FDA Approves Additional Dosing Schedule for Rylaze in ALL and LBL
https://www.onclive.com/view/fda-approves-additional-intramuscular-dosing-schedule-for-rylaze-in-all-and-lbl

Nov 18th, 2022 - The FDA has approved a supplemental biologics license application to add a Monday/Wednesday/Friday (MWF) intramuscular dosing schedule for asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze).1 In June 2021, Rylaze was approved for use a...

see more →